Pharmaceutical Pricing Studio
Optimal launch and rerun prices for existing and new pharmaceutical products, with full worldwide harmonization, payer-mix net-price waterfall, and head-to-head comparison against the six standard pricing models used across NICE, ICER, EU HTA bodies, and PBMs.
HTA / Payer preset
Saved scenarios
Hybrid list price
$288,000
per annual course, United States · upload data in Calibration to fit bands
Net price after rebates
$208,915
gross-to-net 27.5%
Annual revenue (target)
$9,401,184,000
45,000 eligible patients
ROIC over remaining IP life
5042.9%
over 10 yr contribution horizon
Product & clinical inputs
Model outputs — annual price per patient in United States
Cost-plus (COGS + R&D per unit × margin)
$35,716
Value-Based Price ceiling (WTP × ΔQALY)
$240,000
ICER-anchored (comparator + WTP × ΔQALY)
$268,000
External Reference Price (ERP peer basket)
n/a
Tiered Ramsey–Boiteux (Danzon–Towse)
$240,000
Our Hybrid Value–Equity model
$288,000
Country WTP/QALY = $150,000 (Woods et al. + ISPOR tables). Cost-plus assumes 3.5× COGS margin. VBP is the value ceiling. ICER anchors to standard of care. ERP takes the median of 0 peer countries. Hybrid blends value + ICER, lifts for orphan / unmet-need / manufacturing complexity / RWE credibility, softens for budget impact, and applies a Ramsey equity weight vs. US.